A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins

Clinical trial NCT05367843 · TERMINATED

Trial details

NCT number: NCT05367843
Sponsor: Speransa Therapeutics
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

SARS-CoV-2 Infection

Start date: 2022-06-20
Primary completion: 2023-07-18
Enrollment: 103

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.